News & Events about Halozyme Therapeutics Inc.
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, March 15, 2023 Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPROand SC through at...
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target decreased by SVB Leerink from $62.00 to $61.00 in a research report released on Wednesday, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates ...
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 3, 2023 SAN DIEGO, Jan. 3, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ('Halozyme') today...
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target raised by JPMorgan Chase & Co. from $53.00 to $54.00 in a research report sent to investors on Tuesday , Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical companys stock. Several ...
Ticker Report
6 months ago
Halozyme Therapeutics (NASDAQ:HALO Get Rating) had its price target lifted by JPMorgan Chase Co. from $53.00 to $54.00 in a report issued on Tuesday, Benzinga reports. JPMorgan Chase Co. currently has an overweight rating on the biopharmaceutical companys stock. Other ...